Moreover, one study focalized on PSMA-targeting radiopharmaceuticals in differentiating HCC lesions from regenerative nodules in cirrhotic HCC patients, revealing non-significant uptake in the latter [28]. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.